SiBone (NASDAQ:SIBN) Announces Earnings Results

SiBone (NASDAQ:SIBN) announced its quarterly earnings results on Monday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.09, FiscalAI reports. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.13%. The business had revenue of $56.35 million for the quarter, compared to analysts’ expectations of $56.26 million.

Here are the key takeaways from SiBone’s conference call:

• SI‑BONE reported record 2025 worldwide revenue of $200.9 million (up ~20%) and Q4 revenue of $56.3 million, with nearly 22,000 procedures and strong physician adoption gains.
• The company delivered its first full year of positive Adjusted EBITDA ($8.9 million), Q4 Adjusted EBITDA of $5.1 million (9.1% margin), and generated positive free cash flow in Q4 while exiting with $147.8 million in cash.
• Material product and reimbursement catalysts include 510(k) clearance and alpha launch of INTRA Ti, NTAP for iFuse TORQ TNT, TPT for iFuse Bedrock Granite, and a third Breakthrough Device on track for a Q3 510(k) filing with potential late‑2026 commercialization.
• SI‑BONE is expanding commercial reach via a hybrid sales model (89 territory managers + 300+ agents), plans to add 10 territories in 2026, and signed a strategic distribution partnership with Smith+Nephew to accelerate trauma market penetration.
• 2026 guidance targets worldwide revenue of $228.5–$232.5 million (14%–16% growth), ~78% gross margin and ~12.5% OpEx growth, with revenue expected to be weighted to the second half as new product and reimbursement tailwinds ramp.

SiBone Price Performance

Shares of SIBN opened at $15.29 on Wednesday. The stock has a market capitalization of $663.43 million, a PE ratio of -34.75 and a beta of 0.69. The company has a 50 day moving average price of $17.70 and a 200-day moving average price of $16.83. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. SiBone has a fifty-two week low of $12.49 and a fifty-two week high of $21.89.

Analysts Set New Price Targets

Several research firms recently commented on SIBN. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Canaccord Genuity Group lifted their target price on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC increased their price target on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Morgan Stanley raised their price target on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of SiBone in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Insiders Place Their Bets

In other SiBone news, CEO Laura Francis sold 93,475 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $15.32, for a total value of $1,432,037.00. Following the completion of the transaction, the chief executive officer directly owned 544,369 shares in the company, valued at approximately $8,339,733.08. The trade was a 14.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Pisetsky sold 20,756 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $15.35, for a total value of $318,604.60. Following the completion of the sale, the senior vice president owned 285,974 shares of the company’s stock, valued at approximately $4,389,700.90. This trade represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 247,653 shares of company stock worth $4,234,702. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SiBone

Several hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC grew its stake in SiBone by 162.4% in the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock valued at $99,249,000 after acquiring an additional 3,115,001 shares during the period. Cadian Capital Management LP grew its position in shares of SiBone by 96.8% in the fourth quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock valued at $23,094,000 after purchasing an additional 576,100 shares during the period. Wellington Management Group LLP grew its position in shares of SiBone by 74.7% in the third quarter. Wellington Management Group LLP now owns 853,266 shares of the company’s stock valued at $12,560,000 after purchasing an additional 364,897 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of SiBone during the second quarter worth about $4,079,000. Finally, Algert Global LLC raised its position in shares of SiBone by 104.5% during the 3rd quarter. Algert Global LLC now owns 415,194 shares of the company’s stock worth $6,112,000 after purchasing an additional 212,175 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.